There is a significant (and sometimes larger than expected) gap
between "looks like it can compete" and actually competing with a rival
that has both strong data and a big head start, but Merck (NYSE: MRK ) continues to show that it is serious about competing with Gilead (NASDAQ: GILD ) and AbbVie (NYSE: ABBV ) in the market for advanced therapies for hepatitis C (or HCV). The company's nearly $4 billion acquisition of Idenix (NASDAQ: IDIX ) is an expensive affirmation of that long-term focus, but one that could start paying off before the end of the decade.
Continue here:
Will Merck's Bold Hepatitis C Play Pay Off?
No comments:
Post a Comment